scholarly journals Immunization with the Recombinant Cholera Toxin B Fused to Fimbria 2 Protein Protects againstBordetella pertussisInfection

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Noelia Olivera ◽  
Celina E. Castuma ◽  
Daniela Hozbor ◽  
María E. Gaillard ◽  
Martín Rumbo ◽  
...  

This study examined the immunogenic properties of the fusion protein fimbria 2 ofBordetella pertussis(Fim2)—cholera toxin B subunit (CTB) in the intranasal murine model of infection. To this endB. pertussisFim2 coding sequence was cloned downstream of the cholera toxin B subunit coding sequence. The expression and assembly of the fusion protein into pentameric structures (CTB-Fim2) were evaluated by SDS-PAGE and monosialotetrahexosylgaglioside (GM1-ganglioside) enzyme-linked immunosorbent assay (ELISA). To evaluate the protective capacity of CTB-Fim2, an intraperitoneal or intranasal mouse immunization schedule was performed with 50 μg of CTB-Fim2. Recombinant (rFim2) or purified (BpFim2) Fim2, CTB, and phosphate-buffered saline (PBS) were used as controls. The results showed that mice immunized with BpFim2 or CTB-Fim2 intraperitoneally or intranasally presented a significant reduction in bacterial lung counts compared to control groups (P<0.01orP<0.001,resp.). Moreover, intranasal immunization with CTB-Fim2 induced significant levels of Fim2-specific IgG in serum and bronchoalveolar lavage (BAL) and Fim2-specific IgA in BAL. Analysis of IgG isotypes and cytokines mRNA levels showed that CTB-Fim2 results in a mixed Th1/Th2 (T-helper) response. The data presented here provide support for CTB-Fim2 as a promising recombinant antigen againstBordetella pertussisinfection.

2005 ◽  
Vol 25 (5) ◽  
pp. 417-424 ◽  
Author(s):  
Dora Li ◽  
Jennifer O’Leary ◽  
Yan Huang ◽  
Norman P. A. Huner ◽  
Anthony M. Jevnikar ◽  
...  

2004 ◽  
Vol 13 (2) ◽  
pp. 143-153 ◽  
Author(s):  
Tae-Jin Kang ◽  
Nguyen-Hoang Loc ◽  
Mi-Ok Jang ◽  
Moon-Sik Yang

2006 ◽  
Vol 74 (8) ◽  
pp. 4939-4944 ◽  
Author(s):  
F. C. Pimenta ◽  
E. N. Miyaji ◽  
A. P. M. Arêas ◽  
M. L. S. Oliveira ◽  
A. L. S. S. de Andrade ◽  
...  

ABSTRACT One of the candidate proteins for a mucosal vaccine antigen against Streptococcus pneumoniae is PsaA (pneumococcal surface antigen A). Vaccines targeting mucosal immunity may raise concerns as to possible alterations in the normal microbiota, especially in the case of PsaA, which was shown to have homologs with elevated sequence identity in other viridans group streptococci. In this work, we demonstrate that intranasal immunization with a cholera toxin B subunit-PsaA fusion protein is able to protect mice against colonization with S. pneumoniae but does not significantly alter the natural oral or nasopharyngeal microbiota of mice.


Vaccine ◽  
1995 ◽  
Vol 13 (10) ◽  
pp. 933-937 ◽  
Author(s):  
Shi Cheng-hua ◽  
Cao Cheng ◽  
Zhig Jing-sheng ◽  
Li Jiezhi ◽  
Ma Qing-jun

2004 ◽  
Vol 28 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Tae-Geum Kim ◽  
Andreas Gruber ◽  
Ruth M. Ruprecht ◽  
William H. R. Langridge

Sign in / Sign up

Export Citation Format

Share Document